WHAT IS CLAIMED IS:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

A is O or S;

X is a bond or CH_2;

R^1 is selected from the group consisting of H and C_1-C_3 alkyl, wherein C_1-C_3 alkyl is optionally substituted with 1-3 F;

Each R^2 is independently selected from the group consisting of F, Cl, CH_3, CF_3, $-OCH_3$, and $-OCF_3$;

Each R^4 is independently selected from the group consisting of halogen, C_1-C_3 alkyl, $-OC_1$-C_3 alkyl, $-OC(=O)C_1$-C_3 alkyl, and $-S(O)_qC_1$-C_3 alkyl, wherein C_1-C_3 alkyl, $-OC_1$-C_3 alkyl, $-OC(=O)C_1$-C_3 alkyl, and $-S(O)_qC_1$-C_3 alkyl are optionally substituted with 1-3 F;

Each R_5 is independently selected from the group consisting of F, Cl, CH_3, $-OCH_3$, CF_3, and $-OCF_3$;

R_6 is selected from the group consisting of C_2-C_5 alkyl, $-CH_2$Cyclopropyl, and $-C(=O)C_1$-C_3 alkyl, wherein said R_6 substituent is optionally substituted with 1-3 F;

m is 0 or 1;

n is an integer from 1-3;

p is an integer from 0-2; and

q is an integer from 0-2.

2. The compound according to Claim 1, wherein R^1 is H or CH_3.

3. The compound according to Claim 1, wherein R^1 is CH_3.

4. The compound according to Claim 1, wherein A is O.

5. The compound according to Claim 1, wherein each R^4 is independently selected from the group consisting of F, Cl, CH_3, CF_3, $-OCH_3$, $-OCF_3$, $-OCHF_2$, $-OC_2H_5$, $-OC(=O)CH_3$, and $-S(O)_qCH_3$, wherein q is 0, 1 or 2, and n is 1 or 2.

6. The compound according to Claim 1, wherein X is a bond.

7. The compound according to Claim 1, wherein X is CH_2.

8. The compound according to Claim 1, wherein R^6 is selected from the group consisting of n-C_3H_7, $-CH_2$Cyclopropyl, and $-C(=O)C_2H_5$.

9. The compound according to Claim 1, wherein R^6 is n-C_3H_7.

10. The compound according to Claim 1, wherein p is 0 or 1.

11. The compound according to Claim 1, wherein

R^1 is H or CH_3;

Each R^4 is independently selected from the group consisting of F, Cl, CH_3, CF_3, $-OCH_3$, $-OCF_3$, $-OCH_2CH_3$, $-OC(=O)CH_3$, $-OCHF_2$, and $-S(O)_qCH_3$,

R_5 is Cl or F;

R_6 is selected from the group consisting of n-C_3H_7, $-CH_2$Cyclopropyl, and $-C(=O)C_2H_5$;

m is 0;

n is 1 or 2;
p is 0 or 1; and
q is an integer from 0-2.

12. The compound according to Claim 1, wherein

A is O;

R^1 is CH_3;

Each R^4 is independently selected from the group consisting of Cl, $-OCH_3$, $-OCF_3$, and $-S(O)_2CH_3$;

R^5 is F;

R_6 is n-C_3H_7;

m is 0;
n is 1 or 2; and
p is 0 or 1.

13. A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A compound of Claim 1, selected from the compounds listed below, or a pharmaceutically acceptable salt thereof:

1



2



3



4



,

5



,

6



,

7



,

8



,

9



, and

10



.

15. The use of a compound of Claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of Type 2 diabetes mellitus.

16. A pharmaceutical composition comprising

(1) a compound of Claim 1 or a pharmaceutically acceptable salt thereof;

(2) one or more compounds selected from the group consisting of :

(a) PPAR gamma agonists and partial agonists;

(b) biguanides;

(c) protein tyrosine phosphatase-1B (PTP-1B) inhibitors;

(d) dipeptidyl peptidase IV (DP-IV) inhibitors;

(e) insulin or an insulin mimetic;

(f) sulfonylureas;

(g) α-glucosidase inhibitors;

(h) agents which improve a patient's lipid profile, said agents being selected from the group consisting of (i) HMG-CoA reductase inhibitors, (ii) bile acid sequestrants, (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists, (v) cholesterol absorption inhibitors, (h) acyl CoA:cholesterol acyltransferase (ACAT) inhibitors, (i) CETP inhibitors, and (j) phenolic anti-oxidants;

(i) PPARα/γ dual agonists,

(j) PPARδ agonists,

(k) antiobesity compounds,

(l) ileal bile acid transporter inhibitors;

(m) anti-inflammatory agents;

(n) glucagon receptor antagonists;

(o) GLP-1;

(p) GIP-1; and

(q) GLP-1 analogs; and

(3) a pharmaceutically acceptable carrier.